{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:30:09Z","timestamp":1767202209646,"version":"3.48.0"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"R-Pharm International LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: This study aimed to evaluate the pharmacokinetics (PK), effectiveness, and safety of the direct interleukin-6 (IL-6) inhibitor olokizumab (OKZ) in adolescent patients with active polyarticular juvenile idiopathic arthritis (pJIA) who had an inadequate response or intolerance to methotrexate (MTX). Methods: We analyzed results from an open-label, single-arm trial of OKZ therapy at a dose of 64 mg every 4 weeks for 24 weeks. We evaluated pharmacokinetic (PK) parameters, clinical effectiveness, serum C-reactive protein (CRP) dynamics, and adverse events (AEs). Results: Sixteen patients were included in the study, of whom 13 (81.2%) received OKZ through Week 24. The PK profile was consistent with observations in adults with rheumatoid arthritis (RA). By Week 16, 12 (80%) patients achieved an ACRpedi30 response, 11 (73.3%) achieved an ACRpedi50 response, and 2 (13.3%) reached inactive disease status. This response was sustained through Week 24, and no disease flares were observed. A trend toward a better response was noted among patients with baseline CRP &gt; 10 mg\/L, higher baseline IL-6, and those na\u00efve to biologic DMARDs. Twelve patients (75.0%) experienced twenty-three mild or moderate AEs. Infections were the most frequent AEs (in 6 patients, 37.5%). No serious AEs or deaths occurred. Conclusions: OKZ treatment reduced pJIA disease activity and was well tolerated. The safety profile was consistent with that of other IL-6 inhibitors, and the PK profile matched that seen in adult RA patients.<\/jats:p>","DOI":"10.3390\/ph19010079","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:24:58Z","timestamp":1767201898000},"page":"79","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-4721","authenticated-orcid":false,"given":"Ekaterina I.","family":"Alexeeva","sequence":"first","affiliation":[{"name":"Department of Pediatric Rheumatology, National Medical Research Center of Children\u2019s Health, Moscow 119991, Russia"},{"name":"Clinical Institute of Children\u2019s Health Named After N.F. Filatov, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119435, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana M.","family":"Dvoryakovskaya","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, National Medical Research Center of Children\u2019s Health, Moscow 119991, Russia"},{"name":"Clinical Institute of Children\u2019s Health Named After N.F. Filatov, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119435, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina P.","family":"Nikishina","sequence":"additional","affiliation":[{"name":"V.A. Nasonova Research Institute of Rheumatology, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena S.","family":"Zholobova","sequence":"additional","affiliation":[{"name":"Clinical Institute of Children\u2019s Health Named After N.F. Filatov, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119435, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-0608","authenticated-orcid":false,"given":"Valeriya G.","family":"Matkava","sequence":"additional","affiliation":[{"name":"V.A. Nasonova Research Institute of Rheumatology, Moscow 115522, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5732-8873","authenticated-orcid":false,"given":"Elizaveta A.","family":"Krekhova","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, National Medical Research Center of Children\u2019s Health, Moscow 119991, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-6663","authenticated-orcid":false,"given":"Rinat K.","family":"Raupov","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Department, H. Turner National Medical Research Center for Children\u2019s Orthopedics and Trauma Surgery, Saint Petersburg 197136, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8591-7488","authenticated-orcid":false,"given":"Daria V.","family":"Bukhanova","sequence":"additional","affiliation":[{"name":"Medical Department, R-Pharm JSC, Moscow 119421, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina N.","family":"Egorova","sequence":"additional","affiliation":[{"name":"Medical Department, R-Pharm JSC, Moscow 119421, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey A.","family":"Grishin","sequence":"additional","affiliation":[{"name":"Medical Department, R-Pharm JSC, Moscow 119421, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail Yu.","family":"Samsonov","sequence":"additional","affiliation":[{"name":"Medical Department, R-Pharm JSC, Moscow 119421, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-8086","authenticated-orcid":false,"given":"Mikhail M.","family":"Kostik","sequence":"additional","affiliation":[{"name":"Department of Hospital Pediatrics, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"ref_2","first-page":"80","article-title":"Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study","volume":"52","author":"Zak","year":"1999","journal-title":"Horm. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.20953\/1817-7646-2023-3-37-55","article-title":"Situation with medical care for children with rheumatic disease on the example of juvenile arthritis: The view of patients and their parents","volume":"18","author":"Kriulina","year":"2023","journal-title":"Vopr. Prakt. Pediatr. (Clin. Pract. Pediatr.)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.20953\/1817-7646-2022-4-84-103","article-title":"Health care for children with juvenile arthritis in the Russian Federation and in the world","volume":"17","author":"Kriulina","year":"2022","journal-title":"Vopr. Prakt. Pediatr. (Clin. Pract. Pediatr.)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.20953\/1817-7646-2019-3-90-96","article-title":"Pediatric rheumatology care in the Central Federal District of the Russian Federation","volume":"14","author":"Sevostyanov","year":"2019","journal-title":"Vopr. Prakt. Pediatr. (Clin. Pract. Pediatr.)"},{"key":"ref_6","first-page":"394","article-title":"Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis","volume":"30","author":"Bowyer","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_7","first-page":"72","article-title":"Update on treatment of arthritis in children: New treatments, new goals","volume":"64","author":"Lovell","year":"2006","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"ref_8","first-page":"493","article-title":"Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis","volume":"10","author":"Robbioni","year":"1992","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_9","first-page":"1349","article-title":"Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis","volume":"32","author":"Saxena","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2249.1994.tb06551.x","article-title":"Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis","volume":"96","author":"Eberhard","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Caiello, I., Minnone, G., Holzinger, D., Vogl, T., Prencipe, G., Manzo, A., De Benedetti, F., and Strippoli, R. (2014). IL-6 amplifies TLR mediated cytokine and chemokine production: Implications for the pathogenesis of rheumatic inflammatory diseases. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107886"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","article-title":"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: Efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Nasonov","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard-2022-222630","article-title":"Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: Efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"FFeist","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/ard-2023-225473","article-title":"Olokizumab plus methotrexate: Safety and efficacy over 106 weeks of treatment","volume":"83","author":"Feist","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.41879","article-title":"Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis","volume":"73","author":"Trincianti","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/annrheumdis-2013-204186","article-title":"Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score","volume":"73","author":"Consolaro","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrrheum.2013.105","article-title":"Advances from clinical trials in juvenile idiopathic arthritis","volume":"9","author":"Lovell","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2011-201060","article-title":"Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: Results from the Dutch National ABC Register","volume":"72","author":"Otten","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","first-page":"150","article-title":"Minimal clinically important differences of the childhood health assessment questionnaire","volume":"32","author":"Brunner","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_23","first-page":"199","article-title":"Prognostic Factors for the Response to Tocilizumab Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations: A Cohort Study","volume":"17","author":"Alexeeva","year":"2018","journal-title":"Vopr. Sovrem. Pediatr. (Curr. Pediatr.)"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s00296-024-05711-4","article-title":"Clinical outcomes of tocilizumab therapy in polyarticular and systemic juvenile idiopathic arthritis: A single-center analysis (2018\u20132022)","volume":"44","author":"Gazda","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2019-215987","article-title":"Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab","volume":"79","author":"Shafran","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.41528","article-title":"Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial","volume":"73","author":"Brunner","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_27","unstructured":"United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation, Research (CDER), and Center for Biologics Evaluation and Research (CBER) (2025, December 27). Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Available online: https:\/\/www.fda.gov\/downloads\/Guidances\/UCM174090.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Brunello, F., Tirelli, F., Pegoraro, L., Dell\u2019APa, F., Alfisi, A., Calzamatta, G., Folisi, C., and Zulian, F. (2022). New Insights on Juvenile Psoriatic Arthritis. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.884727"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_30","first-page":"40","article-title":"The Russian Version of the Childhood Health Assessment Questionnaires (CHAQ) and the Child Health Questionnaires (CAQ)","volume":"40","author":"Nikishina","year":"2002","journal-title":"Rheumatol. Sci. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0091270011422812","article-title":"Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies","volume":"52","author":"Wang","year":"2012","journal-title":"J. Clin. Pharmacol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/1\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:27:29Z","timestamp":1767202049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/1\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ph19010079"],"URL":"https:\/\/doi.org\/10.3390\/ph19010079","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}